Background-Destination therapy left ventricular assist devices (DT LVADs) are one of the most invasive medical interventions for end-stage illness. How patients decide whether or not to proceed with device implantation is unknown. We aimed to understand the decision-making processes of patients who either accept or decline DT LVADs. Methods and Results-Between October 2012 and September 2013, we conducted semistructured, in-depth interviews to understand patients' decision-making experiences. Data were analyzed using a mixed inductive and deductive approach. Twenty-two eligible patients were interviewed, 15 with DT LVADs and 7 who declined. We found a strong dichotomy between decision processes with some patients (11 accepters) being automatic and others (3 accepters, 7 decliners) being reflective in their approach to decision making. The automatic group was characterized by a fear of dying and an overriding desire to live as long as possible: "[LVAD] was the only option I had…that or push up daisies…so I automatically took this." By contrast, the reflective group went through a reasoned process of weighing risks, benefits, and burdens: "There are worse things than death." Irrespective of approach, most patients experienced the DT LVAD decision as a highly emotional process and many sought support from their families or spiritually. Conclusions-Some patients offered a DT LVAD face the decision by reflecting on a process and reasoning through risks and benefits. For others, the desire to live supersedes such reflective processing. Acknowledging this difference is important when considering how to support patients who are faced with this complex decision. (Circ Cardiovasc Qual Outcomes. 2014;7:374-380.)
T he marvels of modern medicine include an increasing array of aggressive interventions that can improve the quantity and even the quality of life for patients who are dying of progressive illness. One such therapy that is becoming increasingly mainstream is the left ventricular assist device (LVAD) for people with advanced heart failure. This therapy, initially developed as a bridge to transplantation for people who were awaiting a heart, is now being used in the much larger population of patients who are ineligible for transplantation. This so-called destination therapy (DT) promises to grow, with an estimated 150,000 to 250,000 patients annually who may potentially be eligible. 1 Patients offered a destination therapy left ventricular assist device (DT LVAD) are faced with a choice involving complex trade-offs. For DT LVAD eligible patients who forego this therapy, the 2-year survival is dismal at ≈10% 2 ; in comparison, 2-year survival after DT LVAD implantation is 58% and heart failure quality of life measures improve by an average by 178% for those surviving the initial recovery. 3 Yet, these striking benefits come with a host of risks and burdens. The majority of patients experience a major adverse event within 2 years, including reoperation to replace a malfunctioning pump (10%), disabling stroke (11%), and death (33%). 3 Device infection, bleeding, and recurrent hospitalizations are common. Additional burdens include maintaining a constant electric power source, driveline care, costs, and precautions while traveling and bathing. These burdens are borne by patients and caregivers alike. Finally, the most common reasons that patients are ineligible for heart transplantation, and are thus offered a DT LVAD, are advanced age and medical comorbidity. 4 Consequently, even after successful DT LVAD implantation, many patients will be left with chronic illness and progressive frailty. 5 In short, pursuing a DT LVAD is a complicated decision with the potential for both significant benefits and significant risks and burdens.
When making complex medical decisions, one prevailing opinion in the field of decision science argues that if people are able to go through a more effortful, reasoned, and reflective process when making decisions, they will be more likely to make an informed choice consistent with their values. 6 Whether this holds true, particularly among patients with severe illness, is an area of some debate. 7 Currently, no published studies exist exploring how patients considering DT LVAD approach this difficult decision. In this qualitative study, we aimed to understand the decision-making processes of patients who either accept or decline DT LVADs.
Methods

Study Design
We conducted a qualitative study using in-depth, semistructured interviews with patients who were eligible for or had a DT LVAD. A qualitative study design was chosen to gain a comprehensive understanding of a patient's decisional process surrounding the DT LVAD decision and was especially appropriate given the lack of existing data on the topic. The study was approved by the institutional review board at the University of Colorado. Written or verbal informed consent was obtained from all study participants. Participants were compensated $25 for their time.
Sampling and Recruitment
Patients previously offered a DT LVAD and currently followed at the University of Colorado were eligible for the study, including (1) those currently living with an implanted DT LVAD and (2) those who had been offered but declined a DT LVAD. We used cross-sectional sampling of all patients who had gone through DT LVAD decision making and continued purposeful sampling to reach thematic saturation among decliners. The principal investigator (C.M.) directly recruited patients using her established clinical relationships. We excluded patients who were evaluated but ultimately deemed ineligible for DT LVADs, patients initially implanted as a bridge to transplantation, and those who could not provide informed consent. All eligible patients during the study period agreed to participate, and interviews were conducted until thematic saturation was met.
Data Collection
In-depth, semistructured interviews were conducted by C.M. and C.N. in-person or by phone with each of the study participants from October 2012 through September 2013. The principal investigator (C.M.) is a practicing nurse practitioner on the inpatient heart failure service. To avoid bias and coercion related to her clinical relationships, every effort was made to have C.N., who did not have a clinical relationship with the patients, perform the interviews. However, several of the decliners were interviewed by C.M. due to the limited time frame many of them had between the time they declined the DT LVAD and when they transitioned to comfort care. Consistent with study goals and established qualitative research methods, 8 these in-depth, semistructured interviews used broad, open-ended questions to elicit personal thoughts and experiences regarding decision making surrounding DT LVADs. Two question guides were developed (1) for patients who accepted a DT LVAD and (2) for patients who declined a DT LVAD (Supplemental Methods I in Data Supplement). The question guides were based on the Ottawa Decision Support Framework. 9 This framework states that participants' decisional needs (eg, knowledge, values, and support) will affect the decision quality-informed, value-concordant decisions. This impacts subsequent outcomes such as emotions, regret, blame, and behavior. Domains addressed in the interview guide include factors involved in the decision-making process, assessment of clinician interaction, expectations of living with the DT LVAD and unexpected outcomes, future decisions, consideration of alternatives, as well as degree of satisfaction with the decision. The interviews were digitally recorded, professionally transcribed, and reviewed for accuracy.
Patients also completed a short survey with demographic questions, the control preferences scale, 10 and the decision regret scale 11 (Supplemental Methods 2 in Data Supplement). The control preferences scale assesses a patient's preference for an active, shared, or passive role in decision making. The control preferences scale has been validated and used in a variety of patient populations. 12 The decision regret scale is a 5-item scale with high internal reliability (Cronbach αs of 0.81-0.92) and correlation with satisfaction, decision conflict, and quality of life. 11
Qualitative Analysis
Transcripts were entered into ATLAS.ti 7.0 13 software, and data were analyzed using a mixed inductive and deductive approach. [14] [15] [16] We began with a process of exploring each transcript for the language and phrases used by participants to describe their decision-making experiences. To develop a codebook, D.M. and C.N. each coded a subset of interviews separately. Through an iterative, multidisciplinary teambased process, we reviewed and discussed the codes to ensure their completeness and contextual validity. We developed the final codebook incorporating both data-derived codes and formal domain codes defined a priori consistent with our mixed inductive and deductive approach. [14] [15] [16] Open coding, concomitant with team discussion and data reimmersion, was followed by axial coding in which we established links between the a priori and in vivo codes to provide a conceptual and thematic description. Subsequently, C.N. coded the remainder of the interviews. Confirming and disconfirming cases were discussed until consensus was reached. The entire study team-determined thematic saturation was reached as additional interview data created little or no change to the codebook and no new patterns or themes emerged.
We used several strategies to assure trustworthiness of the findings. 17, 18 To assure dependability, an audit trail was kept by C.N. during the analytic phase of the project. To assure transferability, we have attempted to describe our sample in adequate detail so that others can determine how their populations compare. To assure credibility and confirmability, we triangulated our findings using a multidisciplinary study team, consisting of 2 advanced heart failure and transplant cardiologists (L.A. and A.B.), a heart failure nurse practitioner (C.M.), a geriatric and palliative care physician (D.M.), a cardiothoracic surgeon (J.C.), and a qualitative expert (C.N.). Throughout the data analysis, this team met to discuss the analytic process and emergent themes. Additionally, themes were presented to a cardiac health services research group and a palliative care research group to seek input regarding trustworthiness.
WHAT IS KNOWN
• The decision to pursue a destination therapy left ventricular assist device is difficult and complex.
WHAT THE STUDY ADDS
• Patients considering destination therapy left ventricular assist devices seem to have a strong dichotomy in how they approached their decision. Some patients were automatic, focusing on fear of dying and an over-riding desire to live as long as possible.
Other patients were reflective, weighing risks, benefits, and burdens as they made their decision. • Irrespective of approach, most patients experience the destination therapy left ventricular assist device decision as a highly emotional process and many seek support from their families or spiritually. • Acknowledging this difference in decision-making processes is important when considering how to support patients who are faced with this complex decision.
Results
Overview
We interviewed 22 patients who had gone through DT LVAD decision making: 15 who had been implanted with DT LVAD and 7 who had declined. Duration of interviews ranged from 21 to 86 minutes (mean=47 minutes). The average age of patients was 67 years. One patient was a woman and 1 patient was implanted at another center. The time from implant or declination to interview ranged from 90 to 1847 days among accepters and 1 to 93 days among decliners. Only 2 patients with DT LVADs endorsed any decision regret on the decision regret scale, with scores of 20 and 45 on a 100-point scale. 11 All but one patient desired an active role in decision making based on the control preferences scale. 10 Additional summary statistics are provided in Table 1 . It was obvious from the data that patients considering a DT LVAD had reached their decisions differently. Although this was not an a priori dichotomization, nearly all patients clearly fell into 1 of 2 decision-making approaches: (1) an automatic process of decision making where fear of death and a singular focus on DT LVAD as a chance to prolong life over-rode any weighing of additional risks and benefits and (2) a reflective process where participants reasoned through risks and benefits of DT LVAD therapy and were able to see death in the context of other possible future DT LVAD outcomes. Only one patient's approach did not clearly fit into either category, largely based on his inability to focus during the interview. Although not statistically significant, there were differences between the automatic and reflective patients. The automatic group was younger (mean=65), they had a mean educational level of a high school graduate, and all but one was married (n=9). By contrast, the reflective group was older (mean=70), they had a higher educational level (mean=4-year college graduate), and only half were married (n=5).
Regardless of their decision-making approach, the process was a highly emotional experience for all participants. Below, we outline salient features of the 2 types of decision processes that emerged from our data as well as describe secondary influences on DT LVAD decision making.
Dominant Decision Processes: "There Was No Choice" Versus "I Thought About It an Awful Lot"
We found a clear difference in the primary way that patients approached the decision of DT LVAD. Those who seemed to use an automatic decision process had a different decisionmaking experience than those who seemed to use a reflective decision process. Table 2 includes descriptive exemplars for each type of decision-making process.
Patients who seemed to use an automatic decision process did not view DT LVAD implantation as a choice (n=11; 11 accepters). These patients discussed valuing life above any other considerations, including risks of the procedure or burdens of living with the device. Multiple patients in this category talked about having "no choice" but to receive the DT LVAD to "live, not die," or not "push up daisies." All were accepters, essentially by definition, because declining a DT LVAD was antithetical to the over-riding goal of this decision approach. Although not directly using the words scared or afraid, for many, their fear of dying was palpable during the interviews. Some patients told us that they did not want to know about the risks of a DT LVAD because they had decided to move forward with implantation and did not want to hear negative aspects of a therapy that they "had to have." By contrast, patients who seemed to use a reflective decision process had a different experience (n=10; 3 accepters, 7 decliners). These patients viewed death as an option worthy of consideration, examined the meaning of their lives, and reflected on their values, particularly around quality versus quantity of life preferences. Even the 3 reflective patients who ultimately accepted the DT LVAD acknowledged the risks involved and the potential trade-off of choosing life with a potentially risky and burdensome device. Those who declined generally indicated that death was an acceptable alternative to continuing or prolonging a life of pain and suffering, with many saying that they "don't fear death."
Questions around future discontinuation of DT LVAD therapy reinforced this dichotomous decision-making approach. All 3 reflective patients with DT LVADs were able to consider device deactivation in the context of quality of life. For example, when asked if quality of life were low, 1 patient responded: "By all means, I [would] want the LVAD to be turned off." This was in stark contrast to automatic patients, who were either more tentative in their responses about device deactivation or absolutely would not consider it: "Unless somebody shoots me and I'm bleeding to death…and nobody is coming to help…other than that, I don't intend to turn it off at any time." Importantly, for all patients, emotion was apparent in their decision-making process. Both automatic and reflective patients became emotional and even shed tears during their interviews when recalling the decision-making time period.
Secondary Influences
Several other factors seemed to color patients' DT LVAD decision-making process: severe illness, relationships, spirituality, finances, clinician bias, and media influences. Table 3 includes descriptive exemplars for each secondary influence.
Severe Illness
Some patients described themselves as "drugged up" or "confused" while in intensive care units prior to and during their decision, creating a less than optimal decision-making situation.
Relationships
Many patients viewed their families and friends as the most important factor in choosing to receive a DT LVAD. Some patients desired to be with family longer before death. For both accepters and decliners, several patients' families did not agree with their decisions creating tension within relationships.
Spirituality
Many of the patients indicated that spirituality played a role in their decision, from prayers for guidance and protection to church friends' support, or talking with a pastor or spiritual leader about past behaviors.
Finances
Most patients told us their insurance covered or would cover nearly all expenses related to DT LVAD, and consequently, cost was minor or absent in their decision-making process. A few, however, indicated that they were concerned about related expenses that would create a financial burden.
Clinician Bias
Several patients mentioned awareness of the clinicians' preferences that they accept the DT LVAD therapy. Others commented how clinicians' framing of the therapy, including comparison to larger devices no longer in use, helped make the device seem more acceptable. …when they showed me it, I did kind of take a second breath. "Cause I didn't expect it to be that big…but then they showed me the old style one…how big it was…and I'm sure glad I didn't have to get that!" (Accepter 05; >1 y since implant)
They (the LVAD team) basically, right there at the end, were trying to shove it down my throat (Decliner 04; >1 mo since declination) Media …it wasn't really a deciding factor…but I found out that Vice-President Cheney had an LVAD in him and he had it for 12 y before he had a heart transplant…that is a pretty good indication there that it would work (Accepter 04; <1 y since implant)
Media
The Cheney effect seemed to have a sizeable impact on patients' decisions to accept the DT LVAD. Although we heard misinformation from patients about former Vice-President Cheney's LVAD, many conveyed a sense of security because Mr Cheney seemed to have done well.
Discussion
Arguably, DT LVAD is one of the most invasive therapies available in modern medicine. Patients going through this decision process have reached the terminal stage of a chronic progressive illness where they are effectively faced with the decision to live out the remainder of their life dependent on mechanical circulatory support or transition to comfort care. We found that patients considering a DT LVAD diverged sharply in their decision-making processes. Some patients, both accepters and decliners, described going through a reflective decision process involving cognitive weighing of risks and benefits and a consideration of both quality and quantity of life. By contrast, other patients went through an automatic decision process where they never really perceived there to be a decision. They viewed DT LVAD implantation as the only reasonable choice because all other considerations were over-ridden by the central desire to live as long as possible. This group exhibited a strong fear of death. Consequently, other considerations, such as the risks of the procedure and the potential burdens on quality of life, were not important to these patients. To improve decision making for patients with end-stage chronic disease, much work remains to be done. 19 Currently, no published literature exists summarizing the process that patients go through when considering a DT LVAD. More importantly, there is a scarcity of literature on how people make decisions around any major procedure for advanced heart failure (eg, implantable cardioverter-defibrillators and transcatheter aortic valve replacement) and also for other noncardiac terminal diseases (eg, mechanical ventilation for progressive lung disease and chemotherapy for metastatic cancer). 19, 20 Our study demonstrates that for many people, major interventions designed to delay impending death appeal directly to their primal desire for self-preservation and help alleviate their fear of death. This is so strong that many patients do not necessarily wish to know the extent to which the DT LVAD actually accomplishes this stated goal. This is discordant with the current paradigm for informed consent for LVAD, which requires that patients understand the risks of therapy and are offered a description of reasonable alternatives. 21 Interestingly, few patients-regardless of decision-making process-discussed statistical risks or benefits when recalling their experience. Although information is essential for informed consent and helpful to some patients, our results show that cognitive weighing of theoretical risks and benefits played a secondary role in most of the patients' decision-making process. To truly support patients making life-and-death decisions, such as with DT LVAD, one must acknowledge the fears inherent to the dire situation that the patients find themselves in before they will be able to consider additional information or planning for the future.
Further, engaging patients cognitively does not necessitate the removal of emotion from the decision; even our most reflective patients were emotional. We found that during this complex medical decision, emotion was deeply embedded in the decision-making process and was a major tangible theme throughout the interviews. Fear, sadness, and melancholy were pervasive. Notably, the reflective patients could use these emotions to guide values exploration and, with adequate recognition, could complement the cognitive decision-making process. By contrast, some automatic patients seemed paralyzed in their ability to explore various options by their fear of death. Providers must recognize that fear and emotion envelop the decision-making process for any patient. It is important to attend to these emotions throughout their decision as part of any patient-centered process. 22 The Dual-Process Theory of decision making argues that people make decisions either intuitively, drawing on past experiences and emotion, or rationally, using an analysis dominant and reasoned process. 23 Research suggests that people prefer to use intuition for most decisions because making decisions using a reflective process takes cognitive effort, something that we as humans attempt to avoid. 23 Our data provide a clear example of the Dual-Process Theory of decision making, with patients divided between an intuitive, automatic process and a reasoned, reflective process.
An example of how the Dual-Process Theory can help us interpret our data relates to the status quo bias. The status quo bias is a cognitive bias where people would rather accept the default decision than use a reflective decision process. 24 Among patients referred to an academic medical center for consideration of a DT LVAD, the default choice is the DT LVAD, particularly because that is often the primary reason for the referral. In our sample, the automatic patients universally accepted this default therapy. In comparison, a key factor in approaching the DT LVAD decision reflectively is having the ability to consider a shorter life with heart failure and comfort care. These reflective patients were able to see the decision not as life versus death but rather that death was inevitable regardless of the choice made. Consequently, they were able to explore important trade-offs, such as potential modes of death and the balance between quantity and quality of life.
Future research aiming to support DT LVAD decision making should explore the degree to which addressing the fear and emotion associated with this decision can help automatic patients traverse a more reflective process and whether a more reflective process is even a good thing for patients in this situation. Further, future research should test whether a reflective process leads to patients and caregivers who are better informed and better prepared for downstream consequences. Finally, we know that patients resolve cognitive dissonance over time 25 ; a prospective study aiming to explore patients' decision processes at the time of decision making for DT LVAD and then follow their reactions over time would validate or refute our findings.
Limitations
There are several limitations to our study that should be considered when interpreting our data. First, this study was performed at a single academic center with a relatively homogenous sample, including only one female patient; however, we had 100% participation of eligible patients during the first 6 months of the study with only 2 additional decliners subsequently interviewed to assure thematic saturation among decliners. Second, the hospital is a tertiary medical center and patients are referred specifically for advanced heart failure therapies. Consequently, patients who declined DT LVAD therapy upstream in the referral pathway were not included in our sample. However, patients who declined DT LVAD therapy in our study went through the entire evaluation process and their experience most closely represented current DT LVAD decision making. Third, the sample of patients who declined DT LVAD was small although the team is confident that thematic saturation was met. Fourth, patients were interviewed after their decision about DT LVAD. This could bias the results because the patients would be influenced by the outcomes; however, we chose this strategy deliberately so as not to influence the DT LVAD decision-making process with our interviews. Future work could explore the DT LVAD decision process prospectively. Last, themes from qualitative research may reflect the biases of the investigators. To minimize bias, we used several methods, including using a primary interviewer and analyst with no clinical relationship as well as triangulating our findings among the multidisciplinary team.
Conclusions
Overall, decisions surrounding end-stage illness are complex and occur in the setting of high emotion. Patients must be supported in this process, in part, by recognizing that patients will either go through a reflective decision process where they will weigh the risks and benefits or they will go through an automatic process in which they do not perceive there to be a choice. Therefore, any decision support interventions, such as decision coaches or decision aids, will need to consider the psychological, emotional, and cognitive decisional needs of all patients.
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